Copy number variants (CNV)s involving KANK1 are generally classified as variants of unknown significance. Several clinical case reports suggest that the loss of KANK1 on chromosome 9p24.3 has potential impact on neurodevelopment. These case studies are inconsistent in terms of patient phenotype and suspected pattern of inheritance. Further complexities arise because these published reports utilize a variety of genetic testing platforms with varying resolution of the 9p region; this ultimately causes uncertainty about the impacted genomic coordinates and gene transcripts. Beyond these case reports, large case-control studies and publicly available databases statistically cast doubt as to whether variants of KANK1 are clinically significant. However, these large data sources are neither easily extracted nor uniformly applied to clinical interpretation. In this report we provide an updated analysis of the data on this locus and its potential clinical relevance. This is based on a review of the literature as well as 28 patients who harbor a single copy number variant involving KANK1 with or without DOCK8 (27 of whom are not published previously) identified by our clinical laboratory using an ultra-high resolution chromosomal microarray analysis. We note that 13 of 16 patients have a documented diagnosis of autism spectrum disorder (ASD) while only two, with documented perinatal complications, have a documented diagnosis of cerebral palsy (CP). A careful review of the CNVs suggests a transcript-specific effect. After evaluation of our case series and reconsideration of the literature, we propose that KANK1 aberrations do not frequently cause CP but cannot exclude that they represent a risk factor for ASD, especially when the coding region of the shorter, alternate KANK1 transcript (termed "transcript 4" in the UCSC Genome Browser) is impacted.
Introduction
When interpreting genomic data, variants of unknown significance (VOUS) continue to present a challenge for laboratorians and clinicians alike. A variant is more easily interpreted when it impacts a gene that has been previously associated with the clinical symptomatology observed in the patient. There is substantial evidence to suggest that chromosomal microarray (CMA) is warranted for individuals with autism spectrum disorder (ASD) (Manning and Hudgins, 2010) and cerebral palsy (CP) (Oskoui et al., 2015) , so this difficulty with variant interpretation in such patients is increasingly encountered. Moreover, these neurodevelopmental sequelae are both nonspecific and highly heterogeneous, confounding the determination of whether, or to what extent, a variant contributes to the patient's phenotype.
Clinical case reports may be the first step to understanding a variant's clinical relevance. However, when they include differing phenotypes leading to conflicting conclusions, case reports fail to clarify the variant interpretation process. When available, data from large case-control studies may help better understand these differences and support a variant's pathogenicity (or lack thereof). For example, there is conflicting information published in case reports and large case-control studies regarding copy number variation of KANK1 on chromosome 9p24.3. The KANK1 gene (also called ANKRD15, KN motif and ankyrin repeat domains 1) encodes a protein that regulates actin polymerization and cell motility and has two major alternately spliced transcripts with different promoters and several other possible transcripts (Sarkar et al., 2002; Kent et al., 2002) . The longest transcript, NM_015158 (termed "variant 1" in the UCSC Genome Browser build hg19 and referred to in this report as "transcript 1"; genomic coordinates chr9:504,695-746,106) is longer by 158 amino https://doi.org/10.1016/j.ejmg.2018.04.012 Received 3 February 2017; Received in revised form 18 February 2018; Accepted 22 April 2018 acids and shows tissue specific expression, predominantly in heart and kidney. One of the shorter, evolutionary conserved transcripts, NM_ 153186 (termed "variant 4" in the UCSC Genome Browser build hg19 and referred to in this report as "transcript 4"; genomic coordinates chr9:706,806-746,106) is ubiquitously expressed . Transcript 4 contains 11 exons, and exon 1 is non-coding. As a regulator of the actin cytoskeleton, KANK1 has been shown to bind insulin receptor substrate p53 to suppress IRSp53-induced neurite outgrowth . Other 'ankyrin repeat domain' genes have also been implicated as disease causing (for example, ANKRD11 in KBG syndrome (Sirmaci et al., 2011) ).
One commonly cited publication on KANK1 from 2005 describes a four-generation family in which nine individuals displayed congenital CP, spastic quadriplegia, and intellectual disability (Lerer et al., 2005) . Each of these affected individuals inherited a 225 kb deletion of KANK1 from unaffected fathers. KANK1 was demonstrated to be expressed from a single allele in lymphoblastoid cell lines and other tissues in those unaffected fathers as well as in tissues from normal unrelated individuals. This pedigree and expression data led to the authors' conclusion that deletion of KANK1 from the paternal allele (maternal imprinting) is pathogenic for CP, spastic quadriplegia, type 2. To our knowledge, only one other publication reports a KANK1 deletion in a patient with CP and ID, which was inherited from a healthy father (Segel et al., 2015) .
However, Vanzo et al. subsequently reported a three-generation family with a distinct neurodevelopmental phenotype and inheritance pattern (Vanzo et al., 2013) . In this family, an individual with a paternally inherited KANK1 deletion (192 kb) manifested clinical features of ASD, motor delay, and intellectual disability (ID) while the proband's two brothers (who also harbored the paternally-inherited deletion) were entirely unaffected. Other unrelated reports question the presence of imprinted genes on chromosome 9, including individuals with maternal uniparental disomy of chromosome 9 who are either unaffected or have clinical features attributed solely to an "unmasked" autosomal recessive condition (Castanet et al., 2010; Sulisalo et al., 1997; Tiranti et al., 1999; Bjorck et al., 1999) .
Another body of data suggests that KANK1 deletions are not clinically relevant for CP, ASD, or any other phenotype. The Database of Genomic Variants (DGV; dgv.tcag.ca) (MacDonald et al., 2013) , which includes a recently published case-control study by Coe et al. (2014) , lists numerous individuals with CNVs including KANK1 (these can be viewed in UCSC Genome Browser by applying the "Developmental Delay" track housed under "Phenotype and Literature"; genome.ucsc. edu). According to the Coe et al. publication, deletions of KANK1 were not significantly enriched in a primarily pediatric cohort with mixed neurodevelopmental features including ASD, developmental delay (DD), and/or intellectual disability (ID) versus those without similar features (p = 0.911). Of note, the DGV contains a "Gold Standard Variants track" (hg19_dgvgold), which is a curated, dynamic set of variants from select studies within DGV that meet stringent criteria. This cohort illustrates that KANK1 CNVs affect different parts of this gene (see Fig. 1a and b below). Upon deeper assessment of more stringent criteria, it is clear that KANK1 CNVs impacting the coding region of transcript 4 are far less common in controls than currently held notions suggest.
Without a deeper assessment of more refined control datasets such as Gold Standard DGV, a laboratorian or clinician may reasonably conclude that KANK1 CNVs are not sufficient to cause either CP or ASD. However, this information is neither readily searchable or available in many clinical interpretation contexts, nor does it allow for a more detailed assessment of involved portions or distinct transcripts of genes. Therefore, in clinical practice, the sheer amount of "control" individuals with CNVs impacting a gene coupled with case reports become the default lines of evidence for KANK1 variant interpretation.
While part of the complexity in interpreting this region may be due to genetic modifiers, such as point mutations or epigenetic alterations in these individuals, we provide an updated perspective regarding the potential pathogenicity of CNVs that overlap the KANK1 locus on 9p24.3. This includes theoretical assessment of potential transcriptspecific consequences in 16 patients (15 previously unreported) tested in our clinical laboratory. Our review of the data suggests that a critical element for interpretation for this region of terminal 9p may lie in consideration of the specifically impacted KANK1 transcript, which remains to be systematically assessed in the literature. Indeed, despite the high number of individuals with KANK1 CNVs in the Gold Standard DGV track, relatively few interrupt transcript 4 specifically.
Patient data/material
Clinical information on all individuals in our cohort is summarized in Table 1 (relatively localized KANK1 deletions) and Table 2 (relatively localized KANK1 duplications). All CNVs were detected by clinical CMA including both copy number responsive and single nucleotide polymorphic (SNP) probes, passed quality control standards, and were reported based on CLIA protocols; because of this stringency they were not validated by a second methodology.
There are sixteen individuals (12 males/4 females; Patients 1-16) in our cohort with deletions of KANK1. One of these deletions also includes DOCK8 (Patient 1). Age at time of testing ranged from 0.9 years to 16.7 years. According to medical record review, all patients exhibited ASD and/or DD/ID. Two patients also exhibited epilepsy (Patients 1 and 11, Table 1 ).
There are twelve individuals (9 males/3 females; Patients 17-28) in our cohort with duplications that contain part of KANK1, including one pair of siblings (Patients 25 and 26) within KANK1. Eight of these also partially include DOCK8 (Patients 8-24). Age at time of testing ranged from 1.3 to 12.4 years. All patients exhibited ASD and/or DD/ID. Two patients also exhibited seizures (Patient 17 and 27, Table 2 ).
Only two of these patients' medical records indicated or suggested a diagnosis of CP. Patient 11 had a reportedly normal pregnancy and a salmonella infection resulting in sepsis and hospitalization at 2 weeks of age; he had further medical complication during infancy. Patient 17 was born at 27-weeks' gestation and remained in the NICU for three months due to multiple medical complications.
Methods
We searched our internal laboratory database of genomic findings from 22,054 patients who underwent clinical CMA testing from September 2010 through December 2017 for CNVs overlapping genomic region chr9:470,294-746,106 (hg19) that encompass KANK1. There were 67 total cases, but we refined this cohort to focus our assessment on KANK1 clinical relevance and to limit confounding variables (Tables 1 and 2) . Patients were eliminated if they harbored one or more additional clinically reported CNV (n = 10) (Table 3) , if their KANK1 CNV contained genes in addition to KANK1 and neighboring DOCK8 (n = 16) (Table 4 ), or patients with both (n = 13) (Table 4 ). This resulted in 28 patients with a single reported CNV relatively localized to KANK1: 16 with deletions and 12 with duplications. Patient 5 (deletion) was previously reported by Vanzo et al. (2013) and the remaining 27 are novel to published literature.
The platform primarily utilized in this dataset is an enhanced whole genome chromosome microarray (CMA) known as FirstStep Dx PLUS built upon the ultra-high resolution Affymetrix platform with additional probe content designed to optimize testing for individuals with DD/ID and/or ASD (Karen et al., 2016; Hensel et al., 2017) . Three cases in our final cohort of 28 were analyzed with unenhanced Affymetrix arrays. Most tests were performed due to the presence of neurodevelopmental disability (including ASD) and/or congenital anomalies. The sixteen deletions range in size from 24 kb-225 kb. In all cases, KANK1 appears to be partially included in the deletion. In one case, DOCK8 is also partially included. Based on CMA data, fourteen deletions impact only transcript 1, while two patients (Patients 5 and 16) have deletions that encompass both main KANK1 transcripts (transcripts 1 and 4).
The twelve duplications range in size from 59 kb-363 kb. Patient 17 has two non-overlapping duplications isolated to KANK1 and DOCK8 which are 111 kb and 321 kb in size (in Fig. 2 , these duplications are shown on one line). Based on CMA data, in all cases, KANK1 appears to be partially included in the duplication. In eight cases, DOCK8 is also partially included. Five patients (Patients 25 and 26, who are siblings, and Patients 17, 21, and 28) have a duplication that encompasses both KANK1 transcripts, while the other duplications involve only transcript 1.
Discussion
Laboratorians and clinicians experience difficulty when determining the clinical impact of CNVs if published case studies appear to disagree with each other, with robust case-control data, or with publicly available databases. CNVs involving KANK1 clearly illustrate this challenge. We identified 28 out of 22,054 patients in our database who harbor a CNV relatively localized to KANK1. This represents an incidence of 1-in-788 in a cohort of patients with some form of neurodevelopmental disability (this number rises to 1-in-580 if using patients from Tables 1-3 in our dataset). Given their relative frequency, the disagreement between clinical case reports and case-control data regarding clinical significance, we felt that further review was warranted. Specifically, we evaluated CMA data with specific focus on whether CNVs impacting the longer KANK1 transcript (transcript 1), the alternate KANK1 transcript (transcript 4), or both could theoretically be correlated with clinical consequences that result from KANK1 aberration. While deletions and duplications may lead to divergent phenotypes (for example, a loss of function vs. a gain of function of a certain gene or genes), this issue is complex. If a gene is only partially included in a duplication (as is the case for our entire duplication cohort presented here), the mechanism of pathogenicity may actually be loss of function due to gene disruption (Newman et al., 2015) .
Interestingly, a recent case-control study found that duplications involving DOCK8 are significantly more common in individuals with autism or various psychiatric disorders when compared to controls: ASD (p = 0.00384), schizophrenia (p = 0.008), and depression (p = 0.00731) (Glessneret al, 2017). These were not significantly enriched in individuals with ADHD (p = 0.0899). Across all cohorts, DOCK8 exonic duplications did reach genome-wide significance (p = 7.5 × 10 −6 ). Exonic duplications in KANK1 reached suggestive significance (p = 3.45 × 10 −5 ) in the meta-analysis across all cohorts. However, the authors did not discuss a mechanism as to how these duplications may cause these conditions and the same association was not seen with deletions of DOCK8.
While we chose to limit the number of additional genes impacted by the CNVs, we did include cases of KANK1 aberration that also impact DOCK8, which occurred in a significant portion of our cohort (nine of 28; with one deletion and eight duplications). Homozygous loss-offunction mutations in DOCK8 lead to autosomal recessive hyper-IgE recurrent infection syndrome that is not characterized by neurodevelopmental disabilities (DD/ID, ASD, or CP) in either affected patients or their carrier parents (Zhang et al., 2009; Renner et al., 2004) . However, one publication describes two unrelated individuals with ID who have rearrangements disrupting DOCK8 (one deletion including DOCK8 and one with a translocation breakpoint within DOCK8) (Griggs et al., 2008) . It is therefore unclear what role DOCK8 plays in neurodevelopment. Nevertheless, since CNVs impacting both KANK1 and DOCK8 are commonly observed in public databases as well as our cohort, we included them in this series.
There are two limitations of the Coe et al. study as it relates to our data. Firstly, in the paper and supplemental materials, it is difficult if not impossible to readily assess CNVs and corresponding p-values with respect to the specific genes impacted or contained within the CNV. For example, it is not discernible how many of the "Signature" deletions and "Control" deletions under 10 Mb impacted KANK1 only or KANK1 and neighboring DOCK8. This type of dissection would allow a more direct comparison of our data to Coe's case-control data for determination of potential clinical significance with respect to localized CNVs. Secondly, the "control" cohort (including the Wellcome Trust Case Control Consortium) contains newborns who, based on the age-dependent phenotype, would not likely not have been adequately assessed relative to an ASD phenotype. This would skew the statistical analysis.
Although it is clear that KANK1 is deleted or duplicated in both cases and controls, there is an overrepresentation of CNVs impacting transcript 4 in the Coe et al. case cohort as compared to the control cohort. When the corresponding phenotype track is visible in the UCSC genome browser, it appears that there are 39 deletions in cases versus 2 in controls that impact transcript 4 (p = 1.92 × 10 −6 ); similarly, there are 48 duplications in cases versus 12 in controls that impact transcript 4 (p = 0.0007) (p values were calculated via inference for two proportions method). This significant difference could reflect the fact that CNVs impacting transcript 4 are rarer than those impacting transcript 1, possibly due to its smaller size. Alternatively, it may suggest that deletion/disruption of transcript 4 is in fact clinically relevant (or more severe phenotypically) but this effect is masked in large case-control studies that do not discern between included transcripts. This point is made more interesting by the fact that standard DGV contains over 100 individuals with CNVs impacting any part of KANK1, while Gold Standard DGV contains only 22 individuals with CNVs impacting KANK1 transcript 4.
Of the seven patients in our series whose CNV impacts transcript 4, two have deletions (Patients 5 and 16) and four have duplications [Patients 25 and 26 (siblings, inheritance unknown), 17 (maternally inherited), 21, and 28]. Patient 16 could possibly have one of the more severe ASD-related phenotypes within our deletion cohort based on regression (see Table 1 for clinical features/testing indications); this could be random and based on the phenotypic spectrum/variable expressivity of features, could be ascertainment due to detail provided in submitted medical records, or could support the hypothesis that deletion/disruption of transcript 4 is more likely clinically relevant and/or more severe than if transcript 1 alone is impacted.
Interestingly, there appears to be an alternate start site beyond the typical start site for transcript 4. This results in smaller transcripts that may warrant additional considerations for interpretation. According to the BrainSpan database (www.brainspan.org), the last three exons of KANK1 show increased levels of expression in the postnatal brain. Independent mutation analysis suggests that these exons also have a low mutation burden in a normal population, indicating selective pressure to maintain their sequence integrity for normal neurodevelopmental function (Uddin et al, 2014 (Uddin et al, , 2016 . Furthermore, examination of the KANK1 genomic structure across species suggests that transcript 4 and the additional, shorter transcripts (not specified in RefSeq) are closer in evolutionary origin than transcript 1. Taken together, these data suggest an important neurodevelopmental role for transcript 4 and the other shorter KANK1 transcripts. If this is the case it could potentially explain the more severe ASD-related phenotype in Patients 5 and 16. The fact that Patient 5, who also has intellectual disability, has two unaffected siblings with the same deletion raises questions as to its actual causative role (in preparing this review, we reached out to this family and found that they remain healthy and developmentally normal at 16 years and 4 years old); however, this is consistent with widely published observations that the manifestation of autism is subject to reduced penetrance/variable expression among family members carrying identical CNVs (Heil and Schaaf, 2013) .
There have been several publications supporting the presence of an ASD susceptibility locus on distal 9p24 (Vinci et al., 2007; Abu-Amero et al, 2010) . Eighteen out of our 28 (64%) patients had a diagnosis of ASD documented in their medical records. Of the ten that did not, one patient was less than a year old (making ASD a potential diagnosis for the future), nine patients had some other sort of developmental delay, and six had speech deficits in addition to their developmental delay. Thus, it is clear that 27 out of 28 individuals have neurodevelopmental phenotypes.
A widely cited publication on KANK1 abnormalities in a single family suggests a role in spastic quadriplegic cerebral palsy (CP) (Lerer et al., 2005) . Similarly, a second publication identified a paternallyinherited KANK1 deletion in a patient with spastic quadriplegia and ID (Segel et al., 2015) . Only two of the patients in this series has any indication of CP, (Patient 11 -spastic diplegia, Patient 15 -unspecified), and both patient had significant perinatal complications which were likely contributory factors (Drougia et al., 2007) . Thus, our present series does not support a role for KANK1 in the pathogenesis of CP. It is important to consider, however, the vast phenotypic and genotypic variability observed among individuals with CP; further molecular analysis focused on the various CP subtypes may reveal patterns not currently evident in un-delineated cohorts. This type of evaluation is under exploration (Zarrei et al., 2017) and, despite this current body of data, further supports the performance of CMA in individuals with CP.
In summary, the increased use of high resolution CMA technology shows that the region around KANK1 is impacted more frequently in neurodevelopmental disabilities than was once believed (around 1-in-788 of those with neurodevelopmental disabilities and 1-in-580 if considering those with KANK1 aberrations along with a second CNV). Our data could indicate that KANK1 is a dosage-sensitive locus for developmental delay with or without ASD especially when the shorter KANK1 transcript (termed "transcript 4" or "variant 4") is involved. The suggestion in the early literature that abnormalities of KANK1 is causative for CP (based on one family) is not supported by subsequent literature or our experience. The potential contribution of KANK1 CNVs, particularly those impacting transcript 4, to ASD pathogenicity should be seriously considered when found in the diagnostic work-up of such individuals despite the lack of definitive association. Importantly, because this includes retrospective assessment of CMA data and the extent of KANK1 transcript inclusion in the CNVs, we wish to clarify that experimental data were not generated to directly access neural RNA or protein expression. Furthermore, while the CMA platforms clinically utilized in this cohort provide good coverage of the KANK1 region, limitations to CMA technology prevent certainty in determining specific transcript inclusion in CNVs.
Further studies to assess potential modifiers of the impact of KANK1-related CNVs is warranted and may help explain the apparent confusion as to the significance of this gene/region. Sequence analysis of the alternate KANK1 allele, identification of other genomic regions that could represent a two-hit model, or functional analysis will all contribute to our understanding. Additionally, it may be worthwhile to assess epigenetic modifications and other regulatory elements as they relate to this region based on the prior suggestion of random monoalleleic expression (Segel et al., 2015) and the fact that the UCSC genome browser ("Layered H3K27Ac track") shows a concentrated presence of active enhancers upstream of the start site for transcript 4 (Fig. 2) . It is important in evaluating clinical significance of a CNV based on large case-control studies to have adequate phenotypes and condition-relevant age distributions in both groups, as well as more detailed evaluation of the relevant genomic architecture and transcript utilization in relevant tissues. Our analysis of this complex locus highlights both the limits and dynamic nature of genomic understanding; this reinforces the importance of challenging "accepted" information/standards in the face of new data.
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